Overview

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
Phase:
PHASE3
Details
Lead Sponsor:
Akeso